Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Ovid Therapeutics Q4 2025 Earnings Call - OV4071 clearance and clean OV329 7 mg data unlock pediatric expansion and extend runway
Ovid reported a dense set of clinical and corporate wins: regulatory clearance in Australia for OV4071, the company’s first oral KCC2 direct activator, and safety/tolerability readout for a 7 mg dose ...
- Regulatory clearance secured in Australia for OV4071, the company’s first oral KCC2 direct activator, triggering a 30-day exercise window for Series A warrants.
- OV4071 Phase 1 is on track to start in Q2 2026, followed by a ketamine challenge later in the year and patient proof-of-concept studies late 2026 or early 2027.
- OV329 7 mg SAD/MAD cohort (n=11 at 7 mg) reported no treatment-related serious adverse events and no treatment-associated adverse events in the cohort tested.
- +12 more takeaways
Jabil Q2 FY2026 Earnings Call - Intelligent Infrastructure and AI lift revenue, prompting higher full-year guide
Jabil beat guidance in Q2, driven by a broad-based surge in Intelligent Infrastructure tied to AI data center builds, and raised its full-year revenue and core EPS outlook. Management flagged a $1.1 b...
- Q2 revenue $8.3 billion, beating guidance and driven by Intelligent Infrastructure and stronger-than-expected regulated industries results.
- Core operating income $436 million and core operating margin 5.3% for Q2; GAAP diluted EPS $2.08, core diluted EPS $2.69.
- Intelligent Infrastructure was the standout, with Q2 revenue of $4.0 billion, up 52% year-over-year, and a 5.7% segment margin, lifted by cloud/DCI, networking, and capital equipment.
- +16 more takeaways
SailPoint Q4 FY2026 Earnings Call - $1.125B ARR, AI-driven non-human identity surge is the next TAM
SailPoint closed FY2026 with clear scale: $1.125 billion ARR, 28% ARR growth and 38% SaaS ARR growth. Management is selling a simple narrative—SaaS momentum plus AI-driven non-human identities will ma...
- SailPoint finished FY2026 with $1.125 billion ARR, up 28% year-over-year, crossing the $1 billion ARR threshold.
- SaaS ARR grew 38% to $746 million and accounted for roughly 90% of net new ARR in Q4, underscoring a clear SaaS-first momentum.
- Management says non-human identities and AI agents are the largest TAM expansion they have seen; non-human identities drove ~25% of SaaS identity growth in Q4 and now represent 11% of SaaS identities under governance.
- +12 more takeaways
Ocean Power Technologies Q3 FY2026 Earnings Call - Backlog Jumps to $19.9M, Pipeline Nears $164M Fueled by Defense Wins
Ocean Power Technologies reported sharp commercial and defense momentum while results still show the friction of scaling a hardware-heavy business. Backlog hit a record $19.9 million and pipeline expa...
- Record backlog reached $19.9 million, up $12.4 million and 165% year-over-year.
- Pipeline expanded to $163.9 million, an 84% year-over-year increase, with larger multi-asset and USV opportunities.
- OPT received a $6.5 million DHS award, and integration with Anduril positions PowerBuoy systems inside a next-generation defense sensing network.
- +13 more takeaways
Spire Global Q4 2025 Earnings Call - RFGL Push Drives 50% 2026 Core Revenue Growth Midpoint
Spire came into 2026 as a smaller, cleaner, and more focused company. After selling its maritime business and retiring all debt, management reported Q4 core revenue momentum, a materially expanded gro...
- Spire reported Q4 revenue of $15.8 million and full year revenue of $71.6 million, with the full-year decline driven by the April 2025 maritime divestiture.
- Excluding the divested maritime business, Q4 revenue grew 44% year over year and 36% sequentially, the metric management uses to run the business.
- For 2026 management guides core revenue of $75 million to $85 million, which at the midpoint implies about 50% year-over-year growth on an ex-maritime basis.
- +12 more takeaways
Macy’s, Inc. Fourth Quarter 2025 Earnings Call - Bold New Chapter Showing Traction, Bloomingdale’s Leads but Tariffs and Lower Asset Gains Temper Optimism
Macy’s reported a quarter that reads like a strategic proof point, not a victory lap. Q4 and full-year 2025 results beat guidance across sales, comps, EBITDA, and adjusted EPS, driven by the Reimagine...
- Q4 2025 net sales were $7.6 billion, above guidance, with total revenue of $7.9 billion, down 1.1% year-over-year primarily due to last year’s store closures.
- Comparable sales (OLM) rose 1.8% in Q4, materially beating guidance, with go-forward comparable sales up about 2% and Macy’s go-forward comps up 0.6% in the quarter.
- Bloomingdale’s was the star, reporting a 9.9% comparable-sales increase in Q4 and 7.4% for fiscal 2025, driven by broad-based strength across categories and channels.
- +12 more takeaways
Hello Group Q4 2025 Earnings Call - Overseas Surge Offsets Domestic Slump
Hello Group closed 2025 with a clear structural pivot. Group revenue was essentially flat at RMB 10.37 billion, but the story beneath the headline splits cleanly: domestic revenue weakened, falling 11...
- Overseas acceleration was the standout, overseas revenue rose 71% in 2025 to RMB 2.0 billion, and contributed 24% of Q4 revenue versus 14% a year earlier.
- Group total revenue for Q4 2025 was RMB 2.58 billion, down 2% year-over-year; full year revenue was RMB 10.37 billion, down less than 2% year-over-year.
- Domestic weakness persists, mainland China VAS revenue fell 14% in Q4 and full year domestic revenue dropped 11% to RMB 8.37 billion.
- +12 more takeaways
Lifeward Inc. Q4 2025 Earnings Call - Oramed deal funds oral insulin and accelerates robotics push
Lifeward used the quarter to reframe itself from a niche neurorehab med tech firm into a diversified biomedical innovation company, leaning on a strategic transaction with Oramed to provide capital an...
- Strategic Oramed transaction is the defining development, pending closing after shareholder approval, and is presented as the primary source of capital to execute Lifeward’s expansion into biotech and scale med tech initiatives.
- Oramed-related funding includes a $3 million loan already extended and an expected $10 million convertible note upon close, materially improving near-term liquidity assumptions.
- ORMD-0801, Oramed’s oral insulin candidate, will be advanced into a new U.S. study, and Lifeward emphasized the program’s potential clinical benefits from hepatic-first delivery, including less weight gain and no increased hypoglycemia in prior studies.
- +12 more takeaways
H World Group Q4 2025 Earnings Call - Asset-light franchise growth and DH turnaround lift margins
H World reported a steady operational rebound in 2025, led by rapid room additions, an improving RevPAR trajectory and a meaningful profit mix shift toward its asset-light managed and franchised busin...
- Group revenue CNY 25.3 billion in 2025, up 5.9% year-over-year, hitting the high end of guidance.
- Adjusted EBITDA rose 24.2% to CNY 8.5 billion, margin expanded 4.9 percentage points to 33.5%.
- Adjusted net income increased 32.9% to CNY 4.9 billion.
- +13 more takeaways
InspireMD Q4 2025 Earnings Call - CGuard Prime U.S. launch gains momentum, TCAR label and delivery tweaks set the growth cadence for 2026
InspireMD reported clear early traction for CGuard Prime in the U.S. controlled launch, with Q4 2025 revenue of $3.1 million (U.S. $0.87 million, up 74% sequentially) and international sales of $2.3 m...
- Q4 2025 revenue was $3.1 million, up 62% year over year, driven by the U.S. launch and international growth.
- U.S. revenue in Q4 was $866,000, a 74% sequential increase versus Q3 2025; U.S. gross margins are roughly 70% and lifted company-wide gross margin to 37.5% for the quarter.
- International revenue for Q4 2025 was $2.3 million, up 17% year over year, with about 7% of that driven by FX.
- +16 more takeaways